Company Badge
USPTO Data Jan 1 1976 - Oct 20 2026
4 Patents
#361 in Palo Alto, CA
#14,058 in California
#60,671 in US
Ascendis Pharma Inc.
Forward Citations = 3
7 inventors:
Palo Alto, CA, United States of America
Ascendis Pharma Inc.
Calculating rank
% Expired Patents = 25.0
CIPO Patents = 3
EPO Patents = 5
Forward Citations = 3
Loading Chart...
Loading Chart...
7 inventors (with patents filed for the assignee):
Harald Rau (4 out of 58 patents)
Ulrich Hersel (3 out of 42 patents)
Dirk Vetter (3 out of 21 patents)
4. Thomas Wegge (3 out of 38 patents)
5. Robert Schnepf (2 out of 7 patents)
6. Nicola Bisek (1 out of 13 patents)
7. Samuel Weisbrod (1 out of 6 patents)
8. Harald Rau (0 patent)
9. Ulrich Hersel (0 patent)
4 patents:
Company Overview
Ascendis Pharma is a biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's TransCon technology platform enables the creation of prodrug therapies that have the potential to improve patient outcomes and quality of life. Ascendis Pharma's pipeline includes treatments for conditions such as growth hormone deficiency and acromegaly.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ascendis Pharma Inc.. Retrieved from https://idiyas.com/company/ascendis-pharma
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
3 patents (CIPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
5 patents (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]